ALDX — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-07

• the likelihood and timing of the FDA's potential acceptance and approval of the Reproxalap NDA;

• the adequacy of the data included in potential resubmission of the Reproxalap NDA or supplemental responses to the FDA;

• On October 31, 2023 (the AbbVie Option Agreement Effective Date), we entered into an exclusive option agreement (the AbbVie Option Agreement) with AbbVie Inc. (AbbVie), pursuant to which we granted AbbVie an exclusive option (the AbbVie Option) to

• obtain (a) a co-exclusive license in the United States to facilitate a collaboration with us to develop, manufacture and commercialize reproxalap in the United States, (b) an exclusive license to develop, manufacture, and commercialize reproxalap outside the United States, (c) a right of first negot…

• On April 1, 2026, we repaid the outstanding borrowings of $15.0 million, and terminated all outstanding commitments under the Hercules Credit Facility, including principal, accrued interest, and related fees, pursuant to its terms.

Text removed vs the prior filing · source: 10-Q · 2025-11-05

• the adequacy of the data included in the Reproxalap NDA or supplemental responses to the FDA;

• On October 31, 2023 (the AbbVie Option Agreement Effective Date), we entered into an exclusive option agreement (the AbbVie Option Agreement) with AbbVie Inc. (AbbVie), pursuant to which we granted AbbVie an exclusive option (the AbbVie Option) to obtain (a) a co-exclusive license in the United Stat…

• During the nine months ended September 30, 2025 and 2024, our general and administrative expenses consisted primarily of employee-related expenses, including benefits and stock-based compensation for our full-time employees. Other general and administrative expenses include insurance premiums, consu…

• Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources. For the nine months ended September 30, 2025, comprehensive loss is equal to our net loss of $27.4 million and our net unrealized loss on marketable s…

• Research and development expenses. Research and development expenses were $5.4 million for the three months ended September 30, 2025, compared to $12.4 million for the three months ended September 30, 2024. The decrease of $7.0 million was related to a decrease of $4.4 million in external clinical d…

Text added vs the prior filing · source: 10-Q · 2026-05-07

• On March 30, 2026, a purported stockholder filed a putative class action lawsuit (the Securities Class Action) in the U.S. District Court for the District of Massachusetts, against us and certain current and former officers. The lawsuit alleges violations by the defendants of Sections 10(b) and 20(a…

Text added vs the prior filing · source: 10-Q · 2026-05-07

• Our ability to generate revenue will depend on the successful development, regulatory approval and commercialization of reproxalap. We submitted an NDA (the Reproxalap NDA) for reproxalap for the treatment of the signs and symptoms of dry eye disease in December 2022 and on November 27, 2023, we ann…

• controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye” should be conducted. The letter identified concerns with the data from the trial submitted to the Reproxalap NDA that may have affected interpretation of the results, which the FDA stated may be related…

• On March 17, 2026, we announced that we had received a Complete Response Letter from the FDA (the 2026 Complete Response Letter). The 2026 Complete Response Letter stated that there is “a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product w…

• In connection with the review of a potential NDA resubmission or potential approval of the Reproxalap NDA, the FDA could require additional studies or clinical trials, and the submission of the results of those studies or clinical trials before a potential NDA resubmission will be reconsidered, whic…

• Even if reproxalap is approved for the treatment of dry eye disease, the FDA may restrict patient populations or conditions of use.

Text removed vs the prior filing · source: 10-Q · 2025-11-05

• Our ability to generate revenue will depend on the successful development, regulatory approval and commercialization of reproxalap. We submitted an NDA for reproxalap for the treatment of the signs and symptoms of dry eye disease in December 2022. In February 2023, the FDA accepted the Reproxalap ND…

• Additionally, the FDA has substantial discretion in the approval process and may disagree with our interpretation of, or the sufficiency of, the data from our clinical trials. Clinical trial results frequently are susceptible to varying interpretations, and regulatory authorities may disagree on wha…

• populations, include extensive warnings on the product labeling, or require costly ongoing requirements for post-marketing clinical studies and surveillance or other risk management measures to monitor the safety or efficacy of reproxalap.

• pharmaceutical and biotechnology companies to recruit, hire, train, and retain marketing and sales personnel. We would also face competition in the search for third parties to assist with the sales and marketing efforts of reproxalap.

• As part of our growth strategy, we plan to evaluate the development and commercialization of other therapies related to immune-mediated diseases. We will evaluate internal opportunities from our compound libraries, and also may choose to continue to in-license or acquire other product candidates, as…